The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresactable, chemotherapy-resistant peritoneal carcinomatosis.
Ulrich Lauer
No relevant relationships to disclose
Martina Zimmermann
No relevant relationships to disclose
Julia Sturm
No relevant relationships to disclose
Ursula Koppenhoefer
No relevant relationships to disclose
Michael Bitzer
No relevant relationships to disclose
Nisar P Malek
No relevant relationships to disclose
Joerg Glatzle
No relevant relationships to disclose
Alfred Koenigsrainer
No relevant relationships to disclose
Robert Moehle
No relevant relationships to disclose
Falko Fend
No relevant relationships to disclose
Christina Pfannenberg
No relevant relationships to disclose
Tanja Auth
Employment or Leadership Position - Genelux Corporation
Research Funding - Genelux Corporation
Tony Yu
Employment or Leadership Position - Genelux Corporation
Research Funding - Genelux Corporation
Aladar A Szalay
Employment or Leadership Position - Genelux Corporation
Stock Ownership - Genelux Corporation
Research Funding - Genelux Corporation